Jasper Therapeutics, Inc. (JSPRW) Stock Price & Analysis
Jasper Therapeutics, Inc. (JSPRW) fell 2.16% to USD 0.01 as of June 10, 2026 at 13:17 UTC, according to Nexqual real-time market data.
JSPRW last closed at USD 0.01; the session ranged USD 0.01–0.01 on volume of 6,888 shares. Market capitalization is —, with a 52-week range of USD 0.01–0.01 (NCM). Source: Nexqual, June 10, 2026 at 13:17 UTC.
Key Statistics (as of June 10, 2026 at 13:17 UTC)
| Price | USD 0.01 |
|---|---|
| Change | ▼ 2.16% (down) |
| Previous Close | USD 0.01 |
| Open | USD 0.08 |
| Day Range | USD 0.01 – 0.01 |
| 52-Week Range | USD 0.01 – 0.01 |
| Volume | 6,888 shares |
| Market Cap | — |
| Exchange | NCM |
Technical Analysis (JSPRW)
Nexqual's technical model rates JSPRW "BUY" based on 4 bullish and 2 bearish signals across 66 daily candles, as of June 10, 2026 at 13:17 UTC.
| Overall Signal | BUY |
|---|---|
| RSI (14) | 100 (overbought) |
| vs SMA50 | Below (USD 0.02) |
| MACD | 0 (negative) |
Analyst Ratings (JSPRW)
Wall Street analysts rate JSPRW "None", per Nexqual as of June 10, 2026 at 13:17 UTC.
| Consensus Rating | None |
|---|
Earnings (JSPRW)
| Revenue Estimate | $0 |
|---|
Source: Nexqual, June 10, 2026 at 13:17 UTC.
Financials & Fundamentals (JSPRW)
| Gross Margin | +0.00% |
|---|---|
| Operating Margin | +0.00% |
| Profit Margin | +0.00% |
| ROE | -244.21% |
| Debt / Equity | 22.27 |
| Current Ratio | 2.26 |
| Total Cash | $14.14M |
| Total Debt | $757,000 |
| Free Cash Flow | $-40.74M |
Source: Nexqual, June 10, 2026 at 13:17 UTC.
Financial Health Score (JSPRW)
Nexqual rates Jasper Therapeutics, Inc.'s overall financial health "Mixed" across five dimensions, as of June 10, 2026 at 13:17 UTC.
| Growth | Mixed — No data |
|---|---|
| Profitability | Weak — Pre-revenue or very early stage |
| Balance Sheet | Strong — $14M cash, no debt |
| Cash Flow | Weak — Operating cash flow -$69M |
| Efficiency | Critical — ROE -244%, ROA -112.2% |
Ownership (JSPRW)
| Float | 21.88M |
|---|
Source: Nexqual, June 10, 2026 at 13:17 UTC.
Leadership (JSPRW)
Jasper Therapeutics, Inc. is led by Jeetinder Singh Mahal (age 52), President, COO, CEO & Director, per Nexqual as of June 10, 2026 at 13:17 UTC.
| President, COO, CEO & Director | Jeetinder Singh Mahal (age 52) |
|---|---|
| Executive Chairman | Thomas G. Wiggans (age 73) |
| Co-Founder, Member of Scientific Advisory Board & Director | Judith Anne Shizuru (age 68) |
| CFO & Corporate Secretary | Herbert C. Cross (age 53) |
| Senior Vice President of Human Resources | Matthew Ford |
Major Backers & Investors (JSPRW)
Notable institutional backers of Jasper Therapeutics, Inc. include Toronto Dominion Bank, Boothbay Fund Management, LLC, Tenor Capital Management Co., L.p., according to Nexqual as of June 10, 2026 at 13:17 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Toronto Dominion Bank | 43.5% |
| Boothbay Fund Management, LLC | 7.15% |
| Tenor Capital Management Co., L.p. | 5% |
| Walleye Capital LLC | 4% |
| Susquehanna International Group, LLP | 0.56% |
| -T. Rowe Price Health Care ETF | 0.11% |
Source: Nexqual, June 10, 2026 at 13:17 UTC.
From Jasper Therapeutics, Inc.'s Latest SEC 10-K Filing (filed 2026-03-30)
Key Strengths & Strategy (as disclosed to the SEC)
- Patent Application Serial Number 12/447,634 (publication number US 2010/0226927 Al) and know-how for the purpose of depleting endogenous blood stem cells in patients for whom hematopoietic cell transplantation is indicated.    Intellectual Property   Our success depends in part on our ability to obtain and maintain proprietary protection for our product candidates and other discoveries, inventions, trade secrets and know-how that are critical to our business operations.
- It also depends in part on our ability to operate without infringing the proprietary rights of others, and in part, on our ability to prevent others from infringing our proprietary rights.
Partnerships
- We expect to continue to broaden our pipeline with additional mast cell indications.    We have an exclusive license agreement with Amgen Inc. ("Amgen") for the development and commercialization of the briquilimab monoclonal antibody in all indications and territories worldwide.
- The issued U.S. patents would be expected to expire in 2027, absent any applicable patent term extensions.   License Agreement with Stanford   In March 2021, we entered into an exclusive license agreement with respect to the use of briquilimab from the Stanford Office of Technology Licensing to license U.S.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| CELUW | Celularity Inc. | USD 0 | ▼ 51.72% |
| HUMAW | Humacyte, Inc. | USD 0.06 | ▼ 45.45% |
| NRXPW | NRx Pharmaceuticals, Inc. | USD 0 | ▲ 0% |
| SABSW | SAB Biotherapeutics, Inc. | USD 0.01 | ▼ 66.48% |
| SRZNW | Surrozen, Inc. Warrant | USD 0.02 | ▲ 0% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 10, 2026 at 13:17 UTC. This page is informational and not investment advice.